Study to evaluate the effect of ticagrelor versus placebo in reducing Vaso-Occlusive Crises rate in pediatric patients with Sickle Cell Disease.

Trial Identifier: D5136C00013
Sponsor: AstraZeneca
Collaborator:
IQVIA
NCTID:: NCT04293172
Start Date: June 2020
Primary Completion Date: October 2022
Study Completion Date: October 2022
Condition: Heart, Blood & Circulatory - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Egypt Cairo, Egypt, 12655
Egypt Dakahlia, Egypt, 35516
Ghana Accra, Ghana, 233
Ghana Ho, Ghana, 000
Ghana Navrongo, Ghana, 0
India Mumbai, India, 400022
India Nagpur, India, 440012
India Wardha, India, 442004
Italy Genova, Italy, 16128
Italy NAPOLI, Italy, 80138
Italy Padova, Italy, 35128
Kenya Kisumu, Kenya, 40100
Kenya Kombewa, Kenya, 40100
Kenya Nairobi, Kenya, 00200
Lebanon Beirut, Lebanon, 1107 2020
Lebanon Tripoli, Lebanon, 1434
Tanzania Mbeya, Tanzania, 2410
Tanzania Tanga, Tanzania, 5004
Turkey Adana, Turkey, 01130
Turkey Adana, Turkey, 01330
Turkey ANTALYA, Turkey, 07058
Turkey Mersin, Turkey, 33079
Uganda Kampala, Uganda, 10005
United Kingdom London, United Kingdom, E1 1BB
United Kingdom London, United Kingdom, SE1 7EH
United States of America, MA Boston, MA, United States of America, 02115
United States of America, MI Detroit, MI, United States of America, 48201